CN104804092A - Nanometer antibody for resisting B cell growth stimulating factor and use thereof - Google Patents
Nanometer antibody for resisting B cell growth stimulating factor and use thereof Download PDFInfo
- Publication number
- CN104804092A CN104804092A CN201410046314.5A CN201410046314A CN104804092A CN 104804092 A CN104804092 A CN 104804092A CN 201410046314 A CN201410046314 A CN 201410046314A CN 104804092 A CN104804092 A CN 104804092A
- Authority
- CN
- China
- Prior art keywords
- baff
- nano antibody
- antibody
- cell
- stimulating factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003719 b-lymphocyte Anatomy 0.000 title claims abstract description 19
- 230000004936 stimulating effect Effects 0.000 title abstract description 5
- 230000010261 cell growth Effects 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 19
- 230000014509 gene expression Effects 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 210000004027 cell Anatomy 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 23
- 239000013604 expression vector Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000037914 B-cell disorder Diseases 0.000 claims description 2
- 101710112752 Cytotoxin Proteins 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 239000002619 cytotoxin Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 abstract description 56
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 abstract description 53
- 239000000427 antigen Substances 0.000 abstract description 33
- 108091007433 antigens Proteins 0.000 abstract description 33
- 102000036639 antigens Human genes 0.000 abstract description 33
- 238000012216 screening Methods 0.000 abstract description 10
- 230000004663 cell proliferation Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 230000004071 biological effect Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000003472 neutralizing effect Effects 0.000 abstract description 2
- 101000851434 Homo sapiens Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 abstract 1
- 239000000370 acceptor Substances 0.000 abstract 1
- 230000003833 cell viability Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 102000050326 human TNFSF13B Human genes 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 239000012634 fragment Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 9
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 8
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 8
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 8
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 8
- 241001416177 Vicugna pacos Species 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 5
- 230000002860 competitive effect Effects 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 102100031780 Endonuclease Human genes 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000007503 antigenic stimulation Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000000452 restraining effect Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000321096 Adenoides Species 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- -1 Ni+ ion Chemical class 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101100002024 Thermus aquaticus pstI gene Proteins 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000003314 affinity selection Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- XUWPJKDMEZSVTP-LTYMHZPRSA-N kalafungina Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](C)O[C@H]1[C@@H]2OC(=O)C1 XUWPJKDMEZSVTP-LTYMHZPRSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a nanometer antibody for resisting a B cell growth stimulating factor and a use thereof and belongs to the field of biotechnology. The nanometer antibody for resisting a B cell growth stimulating factor has an amino acid sequence shown in the formula of SEQ ID NO. 1 in the sequence table. Through screening of multiple nanometer antibodies with high activity and a latent neutralising capacity, the nanometer antibody 52 for resisting BAFF is obtained. The nanometer antibody can specifically bond with a human BAFF antigen, adjust biological activity of the BAFF antigen and related ligands, and effectively inhibit bonding of the BAFF antigen and its acceptors and production of corresponding signal cascade effects. The nanometer antibody for resisting BAFF can block combination of BAFF and its three related receptors, can substantially inhibit B cell proliferation or viability and can be used for detection and /or treatment on a plurality of BAFF expression abnormity-related diseases.
Description
Technical field
The present invention relates to nano antibody of a kind of anti-B cell growth-stimulating factor and uses thereof, belong to biological technical field.
Background technology
Lymphoma genus is primary in lymphoglandula or adenoid malignant tumour, there are lymphocyte and (or) histiocytic a large amount of hyperplasia, account for the 8th of China's common cancer, and rejuvenation trend is obvious, in recent years sickness rate rises to 6.91/10 ten thousand by 2-4/10 ten thousand, and rise with the speed of annual 5%, annual new patient about 50,000 people, death toll is more than 20,000.It is generally acknowledged that Hodgkin lymphoma is mainly derived from B cell, most non-Hodgkin lymphoma also derives from B cell, has therefore become a kind of new treatment plan by removing B cell treatment lymphoma.
Clinical study finds, the malignant B cells such as lymphoma can synthesize and secrete a kind of albumen of bone-marrow-derived lymphocyte stimulating factor (B cells-activating fact BAFF) by name, belong to tumor necrosis factor superfamily member, it can with the receptors bind expressed on B cell surface, and then activate NF-kB approach, induction anti-apoptotic gene: the expression of Bcl-2, Bcl-xL, reduces the apoptosis of mature B cell.Different subtype B-cell lymphoma patient serum soluble BAFF content compared with normal collator obviously raises, and the progress of BAFF blood plasma level and genovariation and disease, severity and therapeutic sensitivity correlation.
Nano antibody is by the heavy chain antibody of the disappearance light chain found in alpaca blood, through the method for Belgian scientist's applied molecular biology combine with technique nanoparticle science, and the antibody molecule that the up-to-date and molecular weight developed is minimum.It is simple that it has structure, and penetration power is strong, is easy to purifying and expression, avidity and stability high, without series of advantages such as toxic side effecties.
Not yet there is the report of the nano antibody for BAFF at present.
Summary of the invention
The technical problem to be solved in the present invention is to provide nano antibody and the coding gene sequence thereof of a kind of anti-BAFF.
Another technical problem that the present invention will solve is to provide the purposes of the nano antibody of anti-BAFF.
For achieving the above object, the present invention is by the following technical solutions:
A nano antibody for anti-B cell growth-stimulating factor, its aminoacid sequence is for shown in sequence table SEQ ID NO.1.This sequence comprises framework region and complementary determining region; Complementary determining region is CDR1-CDR3; Framework region is for being respectively FR1-FR4; Complementary determining region has the aminoacid sequence being selected from lower group, is specially:
The aminoacid sequence of CDR1: NYHMG
The aminoacid sequence of CDR2: VAAINGRGSRTKYADSVKG
The aminoacid sequence of CDR3: AAGGPEFYRGRLEDYA
The aminoacid sequence of the FR1-FR4 of framework region, is specially:
The aminoacid sequence of FR1: QVQLVDSGGGLVQAGGSLRLSCAASGRSFK
The aminoacid sequence of FR2: WFRQAPGKEREF
The aminoacid sequence of FR3: RFTISRDNAERTVRLEMNSLKPEDTAVYYC
The aminoacid sequence of FR4: YWGPGTQVTVSS
Its amino acid composition order of the nano antibody of described anti-B cell growth-stimulating factor: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.The anti-BAFF nano antibody 52 of (sequence table SEQ ID NO.1) called after.
The nano antibody of described anti-B cell growth-stimulating factor, the homology of the aminoacid sequence shown in its aminoacid sequence and sequence table SEQ ID NO.1 is greater than 80%, is preferably greater than 90%, is most preferably greater than 95%.
One peptide species, is selected from above-mentioned nano antibody, or claims single domain antibody fragment, or claims domain antibody fragment, or " dAb, VH, VHH ".
To encode the gene order of nano antibody of above-mentioned anti-B cell growth-stimulating factor.
Described gene order is the nucleotide sequence shown in sequence table SEQ ID NO.2.
According to specific nucle or aminoacid sequence in anti-BAFF nano antibody variable region of the present invention, can in vitro the antibody weight chain gene that synthetic is identical therewith nucleotide sequence or coding same amino acid nucleotide sequence, thus obtain identical antibody gene or the transformation for genes involved, and obtain anti-BAFF nano antibody or associated protein or polypeptide product.
Comprise the expression vector of described gene order.Carrier can be procaryotic cell expression carrier, eukaryotic expression vector or insect cell expression vector.
Comprise the host cell of described expression vector.Described host cell can be prokaryotic expression cell, eukaryotic expression cell or insect cell, the preferred intestinal bacteria of described prokaryotic expression cell.
The method of the nano antibody of anti-B cell growth-stimulating factor is prepared by described host cell.
Medicinal compositions, it comprises anti-BAFF nano antibody molecule described in one or more as active ingredient, and comprises pharmaceutically acceptable supporting agent.
Described pharmaceutical carriers is selected from the therapeutical agent of cytotoxin, radio isotope, immune modulator, anti-angiogenic agent, antiproliferative, short apoptosis agent, chemotherapeutic or therapeutic nucleic acids.
Described pharmaceutical composition also can adopt the form of the pharmaceutical kit comprising packaging to provide, and described packing pack is contained in separates one or more antagonists in container or in single container.
The nano antibody of described anti-B cell growth-stimulating factor is for the preparation of the purposes of reagent detecting BAFF.Include but not limited to detect capture antigen nano antibody bag in BAFF ELISA reagent by the biotin labeling nano antibody of elisa plate and detectable antigens for double-antibody sandwich enzyme-labeled immunity.
The nano antibody of described anti-B cell growth-stimulating factor is for the preparation of the purposes of the medicine for the treatment of BAFF abnormal expression relative disease; Described BAFF abnormal expression relative disease is B cell non Hodgkin lymphom (non-Hodgkins lymphoma), B cell chronic lymphocytic leukemia, multiple myeloma, the autoimmune disease relating to B cell or inflammatory diseases.
The present invention constructs the pET30a expression vector of BAFF extracellular region polypeptide recombination clone, obtain BAFF extracellular region (BAFFECD) the High Purity albumen with His label, combine with the Ni+ magnetic bead that energy high-affinity is combined with His label protein, the correct space structure of displayed polypeptides, antigen immune alpaca in this format, build specific nano antibody gene pool (nano antibody phage display gene pool), screening immune nano Antibody geometric mean titer, and the specific nano antibody obtaining B-cell stimulating factor (or claims single domain antibody fragment, single domainantibody fragment), this gene is connected with expression vector and recombinates, constructing can at the nano antibody strain anti-BAFF52 of E. coli.Carry out shaking flask small-scale production in laboratory, through Ni+ resin gel affinitive layer purification, can obtain that SDS-PAGE electrophoresis is pure reaches 95%, the nano antibody of about 100mg/L bacterial cultures.
The present invention relates to the multi-form nano antibody (monomer for BAFF, binary or pentamer), all technology (Technical Reference: Tanha J of the nano antibody of preparation B cell growth-stimulating factor (BAFF), Dubuc G, Selection by phage display of llama conventional V (H) fragments with heavy chainantibody V (H) H properties.J Immunol Methods.2002, 263 (1-2): 97-109) (Gueorguieva D, Li S.Identification of single-domain, Bax-specific intrabodies thatconfer resistance to mammalian cells against oxidative-stress-inducedapoptosis.FASEB J.2006, 20 (14): 2636-8) and based on B cell the immunotherapy of (B cell depletion) is removed.Described antibody can play the effect of antagonist, and may be used for external (in vitro), original position (in situ) or body interior (in vivo) detect or treat the mammalian cell relevant to the existence (or shortage) of BAFF or pathologic condition.
The invention provides use BAFF antibody blocking or in and interactional method between BAFF and TACI/ or BCMA.Described antagonist can also block or in and the interaction of BAFF and TACI/ or BCMA.Anti-BAFF-R antibody can be connected with cytotoxic agent or enzyme, or is connected with radio isotope, fluorescent chemicals or chemiluminescence compound.
Advantage of the present invention is: it is high and have the nano antibody of potential neutralising capacity that the present invention screens multiple activity, finally obtains the nano antibody 52 of anti-BAFF.This nano antibody energy specific binding people BAFF antigen, the biologic activity that adjustment is relevant with its part to BAFF antigen, effectively suppress BAFF antigen to its receptors bind and produce corresponding signal cascade effect.Anti-BAFF nano antibody can block the combination of BAFF and its three kinds of associated receptors, significantly suppresses B cell proliferation or survival, and this nano antibody can be used for detecting and/or treat multiple with BAFF abnormal expression relative disease.
Describe the present invention in detail below in conjunction with the drawings and specific embodiments, do not limit practical range of the present invention with this.
Accompanying drawing explanation
Electrophoresis result after Fig. 1: BAFF Extracellular domain protein expression and purification
Fig. 2: Protein G affinity chromatography purifying heavy chain antibody
Fig. 3: alpaca immune serum is tired
The common heavy chain antibody of Fig. 4: the first round PCR and single-chain antibody gene
Fig. 5: the second round VHH antibody object fragment
Fig. 6: sfiI/Pst enzyme cuts PHEN6 carrier
Fig. 7: sfiI/Pst enzyme cuts object fragment
Fig. 8: bacterium colony PCR checking antibody insertion rate
Fig. 9: anti-BAFF nano antibody protein purification result
The anti-BAFF nano antibody of Figure 10: FPLC method purifying
Figure 11: nano antibody and BAFF antigen are in conjunction with dynamic curve
Figure 12: nano antibody is to the competitive inhibitory effect of acceptor BCMA
Figure 13: nano antibody is to the competitive inhibitory effect of acceptor TACI
Figure 14: anti-BAFF52 nano antibody is in vitro to the inhibited proliferation of Raji cell
Embodiment
Embodiment of the present invention are illustrated by the following example.But embodiment of the present invention are not limited to the specific detail of these embodiments, because for the person of ordinary skill of the art, other change is known, or according to directly disclosed content and appended claims are apparent.Therefore, all technology realized based on foregoing of the present invention all belong to scope of the present invention.
Experimental technique described in following embodiment, if no special instructions, is ordinary method; Described reagent and biomaterial, if no special instructions, all can obtain from commercial channels.
The expression of embodiment 1:BAFF Extracellular domain protein
The fishing of 1.sBAFF gene is got: extract normal people's venous blood, conventionally extract peripheral blood mononuclear cell (PBMC).The extracting of RNA is carried out according to the specification sheets of Invitorgen company.Get 3ug RNA reverse transcription and prepare cDNA masterplate, using it as template, amplification BAFF gene.
Primer sequence is:
5’CGGGAATTCCTGGTGCCACGCGGTGCCGTCAGGGTCCAGAAG3’（SEQ ID No.3）
5’CCCAAGCTTTCACAGCAGTTTCAATGC3’（SEQ ID No.4）
PCR reaction conditions:
2. the structure of expression vector: pcr amplification product agarose gel electrophoresis is separated, reclaims, use EcoRI(BioLab company), HindIII(BioLab company) digestion after, with the carrier pET-30a(Sigma of same ferment treatment) carry out cohesive terminus connection in the end ratio of 3:1.Connect product and press CaCl2 conversion method transform competent E. coli JM109(Sigma), utilize kalamycin resistance to screen recombinant clone.Extract the plasmid DNA of positive colony, carry out EcoR I, HindIII double digestion and agargel electrophoresis analysis, and carry out bacterium colony PCR.By positive recombinant correct for preliminary evaluation, deliver Shanghai Bo Ya Bioisystech Co., Ltd, Shanghai Shen Neng lottery industry Bioisystech Co., Ltd carries out DNA sequence analysis, and the sequence of known in sequencing result and database is compared.
3. the expression of goal gene: with the expression vector containing the correct BAFF gene that checks order, by CaCl2 conversion method transform competent E. coli BL21(Sigma); Meanwhile, not contain the empty carrier Plastid transformation competence e. coli bl21 of BAFF gene as negative control.The single bacterium colony of picking, is inoculated in the LB substratum containing kantlex, after being cultured to logarithmic phase, adding or does not add IPTG and continue to cultivate, the expression of induction goal gene in 37 DEG C.Take a morsel the nutrient solution of induction, non-Induction of bacterial, centrifugal, precipitation.After removing supernatant, thalline is joined in SDS sample loading buffer and boil, the expression of analysis purposes albumen.
4. the great expression of target protein and purifying: select single colony inoculation in containing in the LB substratum of kantlex, after LB is cultured to logarithmic phase, adds IPTG and continues overnight incubation in 30 DEG C.By bacterial culture fluid in 4 DEG C with the centrifugal 15min of 12000r/min.After collecting the suspension of bacterium bacterial lysate, with ultrasonic disruption thalline.After centrifugal, collect bacterial supernatant and inclusion body precipitation respectively.With nickel chelating sepharose (Beijing Vector Gene Technology Co., Ltd) for column packed medium, affinity chromatography is carried out to the extracting solution of bacterial supernatant.The wash-out of target protein adopts the concentration raising imidazoles to complete.Collect the imidazoles elution peak sample of different concns, with SDS-PAGE analysis purposes albumen.) (Fig. 1)
The aminoacid sequence of BAFF Extracellular domain protein is for shown in sequence table SEQ ID No.5:
AVQGPEETVTQDCLQLIADSETPTIQKGSYTFVPWLLSFKRGSALEEKENKILVKETGYFFIYGQVLYTDKTYAMGHLIQRKKVHVFGDELSLVTLFRCIQNMPETLPNNSCYSAGIAKLEEGDELQLAIPRENAQISLDGDVTFFGALKLL（SEQ ID No.5）
Embodiment 2: the structure of anti-BAFF specific nano antibody library
1. immune alpaca, enzyme exempts from methods analyst nano antibody production.
Alpaca neck dorsal sc multi-point injection antigen amounts to 1.5mg, and adds freund adjuvant, point 4 immunity, and tracing observation injection enclosed mass absorbing state, to confirm that immunity is correct.First time immunity measured serum antibody titer (Fig. 2) after one month; Thereafter immunity, each immunization interval time reduces by half, and mensuration is tired.With Protein G post, affinity chromatography method is separated the serum of after the 4th immunity one week, and ELISA method detects heavy chain antibody production and antibody titer, and after the 4th immunity, alpaca immune serum is tired and can be reached 1:10000.(Fig. 3).
2. be separated alpaca peripheral blood lymphocyte
Be separated alpaca peripheral blood lymphocyte, with RNA extraction agent box (QIAGEN), from the lymphocyte obtained, extract total serum IgE.
3. nested PCR method obtains camel antibody heavy chain variable region-VHH.
For improving specific amplification, reverse transcriptase primer adopts the special primer of heavy chain antibody, synthesis cDNA first chain, with this template, carries out pcr amplification heavy chain antibody VHH gene fragment respectively with two cover primers.Adopt nested PCR method, what be greater than 800bp for the first time in pcr amplification is common heavy chain gene segment, the heavy chain antibody genes fragment (Fig. 4) for disappearance light chain between 800 ~ 500bp, cut glue and reclaim disappearance light chain heavy chain antibody gene segments, obtain VHH goal gene (500bp) (Fig. 5) through pcr amplification as template VHH Auele Specific Primer.
The synthesis of diversity primer:
Heavy Chain Fd5’primers:
YTCh-1:CGC CAT CAA GGT ACC AGT TGA(sequence table SEQ ID NO.6)
YTCh-2:GGG GTA CCT GTC ATC CAC GGA CCA GCT GA(sequence table SEQ ID NO.7)
Heavy Chain Fd3’primers:
YT1BN:GCC CAG CCG GCC ATG GCC SMK GTR CAG CTG GTG GAK TCTGGG GGA G(sequence table SEQ ID NO.8)
YT2BN:GCC CAG CCG GCC ATG GCC CAG GTA AAG CTG GAG GAG TCTGGG GGA G(sequence table SEQ ID NO.9)
Connection and the electricity of 4.VHH fragment and Vector for Phage Display transform TG1 competence.
(1) SfI single endonuclease digestion VHH fragment:
Mixing, of short duration centrifugal. put enzyme in 50 DEG C of PCR instrument and cut through night, purifying enzyme cut after PCR primer.
(2) SfI single endonuclease digestion vector plasmid:
Mixing, of short duration centrifugal, put enzyme in 50 DEG C of PCR instrument and cut through night, gel reclaims test kit (QIA) purifying.
(3) pstI single endonuclease digestion vector plasmid:
Mixing, of short duration centrifugal put 37 DEG C of water-bath enzymes cut 1h PCR primer purification kit (QIA) purifying enzyme cut after plasmid vector, 1% agarose gel electrophoresis, qualification plasmid.
(4) linked system:
Of short duration centrifugal after mixing, put 16 DEG C of PCR instrument and connect 28h.
By VHH fragment and pHEN6 carrier (Conrath, KEM other.Antimicrob Agents Chemother (Antimicrobial Chemotherapy) 2001,45:(10) 2807-12., Chinese patent ZL20111028003.1) cut through SfiI/PstI enzyme respectively and connect (Fig. 6-7), electricity is converted in TG1 competent cell, spread plate, verifies antibody insertion rate through bacterium colony PCR.Recombination cloning efficiency detects: on power taking transformed bacteria liquid coating LB/Amp flat board, 32 DEG C, incubated overnight, the joint efficiency of the method validation antibody of secondary daily bacterium colony PCR, the joint efficiency of phage antibody library is more than 90%.(Fig. 8)
The storage capacity of 5.VHH Antibody geometric mean titer and multifarious qualification and preservation
The total tank farm stock of conversion is multiplied by according to the titre transforming rear mensuration.In addition, select 20 ~ 50 positive colonies screening plated growth after electricity turns at random, order-checking, if do not have tumor-necrosis factor glycoproteins to occur, can judge that its diversity is good.After residue bacterium liquid being added the cultivation in 2 hours of appropriate 2YT/Amp substratum, glycerol adding packing, frozen in-80 DEG C, thus obtain the VHH type Antibody geometric mean titer of BAFF immunity.
The preparation of 6.VHH phage antibody library and elementary Function Identification
Antibody library adds helper phage M13K07(Invitrogen) save: 1 μ l M13K07 is added in the infected cell containing 6ml2YT, 0.4ml20%glucose+4 μ l Amp (100mg/ml) substratum, after 37 DEG C of standing 15min, this 6ml substratum is added to containing 92ml2YT, in the substratum of 92 μ lAMP, leave standstill 15min, after 37 DEG C of 250rmp, 1h, add 100 μ l Kan (50mg/mL) 37 DEG C and spend the night.After rescue, supernatant gets the elementary Function Identification of 100 μ l for antibody library, remainder PEG8000 precipitating phage, and under 4 DEG C of conditions, centrifugal collecting precipitation, preserves and measure phage antibody library titre.
Embodiment 3: the acquisition of anti-BAFF nano antibody
1. the screening of anti-BAFF specific nano antibody
With biotinylation BAFF antigen, go out the nano antibody of anti-BAFF from phage library screening antibodies with Streptomycin sulphate avidin magnetic bead method.Biotin labeled BAFF antigen and phage antibody library are mixed in proportion, 4 DEG C of reactions are spent the night.Antigen-phage antibody mixture is added in the EP pipe containing Streptavidin MagneSphere, end rotation 0.5h, magnetic bead is fully combined with biotin labeled antigen-phage antibody mixture.After each rinsing of PBST (0.05%T20), PBS 10 times, use TEA wash-out bacteriophage, room temperature leaves standstill 10min.Close TEA in 1M Tris-HCl, preserve on ice.By phage-infect semilog phase growth TG1, after getting the dilution of appropriate bacterium liquid, coating AMP/LB is dull and stereotyped, 32 DEG C of cultivations, measure elutriant titre, after all the other bacterium liquid enlarged culturing with M13K07 superingection and shaking culture spend the night, within 2nd day, collect supernatant, purify with PEG, after concentrated, be the secondary phage antibody library for next round screening.Take turns screening through 3, the titre of specific phage antibody obtained after measuring often wheel screening, and calculate often wheel screening phage drop into output ratio (rate of recovery) as the index of specific phage antibody enrichment.
Table l: affinity selection is to the enrichment effect of phage antibody
2. Phage-ELISA method selects positive colony
The random single bacterium colony of picking from the agar plate that the 3rd takes turns screening growth bacterium colony, is seeded in 96 well culture plates of the 2YT liquid nutrient medium containing Amp and cultivates, with helper phage superingection abduction delivering phage antibody.Results express supernatant, are that antigen carries out ELISA mensuration with BAFF, pick out the positive hole of BAFF, through DNA sequencing to identify the gene order that anti-BAFF nano antibody is cloned.Obtain a series of nano antibody gene orders comprising sequence table SEQ ID NO.2 gene order, for expressing and screen specificity, highly active nano antibody further.
Embodiment 4: the structure of specific nano antibody expressing plasmid
The specific nano antibody gene that pcr amplification embodiment 3 obtains, and obtain with restriction enzyme BbsI and BamHI site PCR primer, PCR primer and carrier (pSJF2 carrier) (kim Is.Biosic Biochem.2002 is processed respectively with restriction enzyme BbsI and BamHI, 66 (5): 1148-51, Chinese patent ZL201110280031), restructuring is connected through T4 ligase enzyme, and obtain and at the plasmid BAFF52pSJF2 of E. coli, and gene sequencing can be carried out to determine the exactness of its sequence.
1. obtain the pcr amplification condition of VHH goal gene, the composition of 50 μ l PCR system:
PCR reaction conditions:
Positive-sense strand primer-TATGAAGACACCAGGCCCAGGTRMAGCTGGWGGAGTCT; (sequence table SEQ ID NO.10)
Antisense strand primer---GAAGATCTCCGGATCCTGAGGAGACGGTGACCTGGGT.(sequence table SEQ ID NO.11)
2. the enzyme of goal gene is cut:
3. the enzyme of vector plasmid is cut:
Mixing, of short duration centrifugal, put enzyme in 37 DEG C of water-baths and cut 1h, the object fragment after cutting with glue recovery test kit recovery enzyme and plasmid vector.
4. connect goal gene and carrier
Following component is added successively in 1.5ml Eppendorf pipe:
Of short duration centrifugal after mixing, connect 18h in 16 DEG C, obtain the plasmid of specific nano antibody expressing plasmid BAFF52-pSJF2.
Embodiment 5: the expression and purification of anti-BAFF nano antibody
1. nano antibody albumen is at expression in escherichia coli, purifying:
(1) by described in embodiment 4 containing plasmid BAFF52-pSJF2 strain inoculation containing aminobenzylpenicillin LB culture plate on, 37 DEG C are spent the night.
(2) select single colony inoculation in 20ml containing aminobenzylpenicillin LB nutrient solution in, 37 DEG C, shaking table overnight incubation.
(3) transferred species is in 1L containing in the 2YT nutrient solution of aminobenzylpenicillin, and 37 DEG C of shaking tables are cultivated, 240 revs/min, when cultivation reaches 0.6 ~ 1.0 to OD value, add 0.1 ~ 0.5M IPTG, continue overnight incubation.
(4) centrifugal, receive bacterium.
(5) add and melt bacterium enzymatic lysis bacterium, centrifugal, receive solubility nano antibody albumen in supernatant.
(6) obtain through Ni+ ion affinity chromatography high-pressure liquid phase the albumen that purity reaches more than 95%.
The anti-BAFF nano antibody albumen of expressing, through Ni+ resin gel affinitive layer purification, No. 1-4 elutes anti-BAFF nano antibody for 250mM imidazoles, and M is standard molecular weight albumen marker, shown in purifying protein SDS-PAGE result, purifying protein purity can reach more than 95%.(Fig. 9)
2. fast protein liquid chromatography:
(1) antigen and damping fluid prepare: with 0.22 μm of filtering with microporous membrane protein solution and PB damping fluid.
Chromatography column prepares: balance Superdex75TM chromatography column with PB damping fluid (PH7.2), flow velocity is 0.5ml/min.
(2) Sample Purification on Single: with syringe, 1ml nano antibody sample is injected sample loop, flow velocity is 0.5ml/min, automatically measures the A280nm value of elutriant with UV-detector, collects the nano antibody of required purifying.
Shown by the experiment of molecular sieve dextrane gel (superG75) filtration high pressure liquid phase analysis, the time of the elution peak appearance of anti-BAFF nano antibody, the molecular weight of its peak value should be 15kd through compared with standard molecular weight albumen Marker.(Figure 10)
Order-checking obtains the aminoacid sequence of anti-BAFF nano antibody 52 for shown in sequence table SEQ ID NO.1.
Experimental example 6: biological membranous layer interference technique antagonism BAFF nano antibody avidity determination experiment
1. biotinylated antigen prepares: first by even by the mixed in molar ratio of 1:3 with vitamin H for the BAFF antigen (preparation of embodiment 1 method) be dissolved in PBS, room temperature leaves standstill 0.5h, then free biotin molecule is removed by the ultrafiltration of 10KD super filter tube, obtain biotinylated BAFF antigen, and measure the concentration of biotinylated antigen.
2. antibody prepares: Broford method measures antibody concentration, diluting anti-BAFF nano antibody with PBST (0.005%T20) is 20 μMs, 10 μMs, 5 μMs, 2.5 μMs, 1.25 μMs 5 different concns, if 20 μMs of anti-CD20 antibodies (R & D) are unrelated control.
3. envelope antigen: biotinylated antigen PBST (0.005%T20) damping fluid is diluted to 20 μ g/ml, then (Fortebio in OctetQk system, pull company), 6 SA sensors are placed in antibody-solutions and react, antigen is coupled on SA sensor.
4. antigen and antibodies dynamic analysis: in OctetQk system, bag is placed in respectively BAFF nano antibody and the control antibodies solution of 5 different concns by the sensor of antigen, effect 300s, the antigen of antibody on sensor is combined, then sensor is placed in PBST solution, make the antibody dissociation being combined in chip surface, Dissociation time 1500s.In this process, machine can automatically record antigen and antibodies, the real-time information of dissociating.
5. affinity costant calculates: the data obtained analysis software carries out the matching of 1:1Langmuir combination model, calculates the kinetic constant that antigen-antibody combines.Binding constant: kon (1/Ms): 5.71E+03, dissociation constant: kdis (1/s) 1.82E-02; Avidity: KD (M) 3.18E-06.
Biological membranous layer interference technique method measures and dynamic analysis the avidity of nano antibody, the nano antibody of different concns (20 μMs, 10 μMs, 5 μMs, 2.5 μMs, 1.25 μMs) is used to be combined with BAFF antigen respectively, by binding constant and dissociation constant, the avidity of calculating antibody is 3.18E-06.(Figure 11)
Embodiment 7: anti-BAFF nano antibody 52 is tested with the ELISA Competitive assays of acceptor BCMA/TACI
1.0.05M NaHCO
3(pH9.5) dilute BAFF antigen (prepared by embodiment 1) to 10 μ g/ml, antigen coated 2 piece of 96 orifice plate of 100 μ l, 4 DEG C are spent the night.
2.300 μ l0.5%BSA-PBS close 96 orifice plates, 37 DEG C of 2h.
3. first in the plate hole of the 1st piece of 96 orifice plates, add the BCMA(B cell maturation antigen that concentration is 50 μ g/ml, Sigma) 50 μ l, then by anti-BAFF nano antibody with finite concentration dilution proportion, add by 50 μ l/ holes, 37 DEG C, 1h.
Negative control Anti-CD20(R & D company)
Table 2: nano antibody is to the competitive inhibitory effect of acceptor BCMA
4., according to the 3rd step application of sample way, in the plate hole of the 2nd piece of 96 orifice plates, add TACI(cross-film activator and cyclophilin interactant that concentration is 10 μ g/ml, Sigma) 50 μ l, again by anti-BAFF nano antibody with finite concentration dilution proportion, add by 50 μ l/ holes, 37 DEG C, 1h.
Table 3: nano antibody is to the competitive inhibitory effect of acceptor TACI
5. doubly diluted by 1:5000 by HRP-GAH-Ig-antibody (Goat anti human two of horseradish peroxidase-labeled resists, Abbkine company), every hole adds 100 μ l, after 37 DEG C of 1h, washes plate three times with 0.05%PBST.
6. add TMB100 μ l, lucifuge room temperature leaves standstill 20min.
7.1mol/LHCl100 μ l termination reaction.
8. measure the sample OD value under 450nm wavelength by microplate reader.
Figure 12 and Figure 13 shows, in the competitive ELISA experiment that the acceptor TACI of nano antibody and BAFF antigen, BCMA and BAFF antigen combine, find that nano antibody has certain restraining effect to TACI, (inhibiting rate is 29%) and act on special (unrelated control anti-CD20 nano antibody result is negative).
Embodiment 8: anti-BAFF nano antibody stimulates the restraining effect of Raji cell proliferation to BAFF
1. cell cultures: Raji cell (human B lymphocyte knurl, is purchased from ATCC) is in 1640 substratum (Gibico company) of 10%FBS in 37 DEG C, cellar culture under 5%CO2 condition.
2. cell counting: counting culturing cell, is mixed with 10 by cell
6after the cell suspension of/ml, be added in 96 porocyte culture plates with every hole 100 μ l, every hole about 10
5individual cell.
3.BAFF stimulates Raji cell proliferation: by BAFF antigen (prepared by embodiment 1) by final concentration 0ng/ml, 125ng/ml, 250ng/ml, 500ng/ml, 750ng/ml, 1 μ g/ml, control group is 100 μ l serum-free modified form RPMI-1640 substratum, often group establishes 3 repeating holes, after cultivating 24h, 48h, 72h respectively, add the CCK-8(Doj indo Laboratories of 10 μ l), in 37 DEG C, continue cellar culture 5h under 5%CO2 condition.Under 450nm wavelength, detect the absorbance in each hole, observing BAFF stimulates Raji cel l proliferation.
Table 4:BAFF stimulates Raji cell proliferation
4. nano antibody suppresses the increment of cell: after BAFF antigenic stimulation Raji cell proliferation 24h and 48h, adding anti-BAFF nano antibody 52 makes its final concentration be 0 μ g/ml, 25 μ g/ml, 50 μ g/ml, 75 μ g/ml, 100 μ g/ml, often organize 3 multiple holes, continue culturing cell 48h, 24h respectively again, make BAFF antigenic stimulation Raji cell proliferation reach 72h.
Figure 14 shows, and the BAFF antigen of 750ng/ml is to stimulation Raji cell 72h, and cell is obviously shown in propagation as seen.After BAFF antigenic stimulation 48h, add nano antibody, the restraining effect of on cell proliferation is more obvious.
Claims (10)
1. a nano antibody for anti-B cell growth-stimulating factor, is characterized in that: its aminoacid sequence is for shown in sequence table SEQ ID NO.1.
2. the nano antibody of anti-B cell growth-stimulating factor according to claim 1, is characterized in that: the homology of the aminoacid sequence shown in its aminoacid sequence and sequence table SEQ ID NO.1 is greater than 80%, is preferably greater than 90%, is most preferably greater than 95%.
3. the gene order of the nano antibody of the anti-B cell growth-stimulating factor of coding described in claim 1 or 2.
4. the gene order of the nano antibody of the anti-B cell growth-stimulating factor of coding according to claim 3, is characterized in that: described gene order is the nucleotide sequence shown in sequence table SEQ ID NO.2.
5. comprise expression vector and/or the host cell of gene order described in claim 3 or 4.
6. the method for the nano antibody of the anti-B cell growth-stimulating factor described in claim 1 or 2 is prepared by the host cell of claim 5.
7. medicinal compositions, is characterized in that: it comprises anti-BAFF nano antibody molecule described in one or more claims 1 or 2 as active ingredient, and comprises pharmaceutically acceptable carrier.
8. pharmaceutical composition according to claim 7, is characterized in that: described pharmaceutical carriers is selected from the therapeutical agent of cytotoxin, radio isotope, immune modulator, anti-angiogenic agent, antiproliferative, short apoptosis agent, chemotherapeutic or therapeutic nucleic acids.
9. the nano antibody of the anti-B cell growth-stimulating factor described in claim 1 or 2 is for the preparation of the purposes of reagent detecting BAFF.
10. the nano antibody of the anti-B cell growth-stimulating factor described in claim 1 or 2 is for the preparation of the purposes of the medicine for the treatment of BAFF abnormal expression relative disease; Described BAFF abnormal expression relative disease is B cell non Hodgkin lymphom, B cell chronic lymphocytic leukemia, multiple myeloma, the autoimmune disease relating to B cell or inflammatory diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410046314.5A CN104804092B (en) | 2014-01-29 | 2014-01-29 | A kind of nano antibody of anti-B cell growth-stimulating factor and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410046314.5A CN104804092B (en) | 2014-01-29 | 2014-01-29 | A kind of nano antibody of anti-B cell growth-stimulating factor and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104804092A true CN104804092A (en) | 2015-07-29 |
| CN104804092B CN104804092B (en) | 2018-03-27 |
Family
ID=53689315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410046314.5A Expired - Fee Related CN104804092B (en) | 2014-01-29 | 2014-01-29 | A kind of nano antibody of anti-B cell growth-stimulating factor and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104804092B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108251442A (en) * | 2018-02-07 | 2018-07-06 | 中国医学科学院血液病医院（血液学研究所） | FLT3 Chimeric antigen receptors and its application |
| CN110776564A (en) * | 2019-10-30 | 2020-02-11 | 西北农林科技大学 | Two-strain anti-newcastle disease virus nano antibody and expression preparation method and application thereof |
| CN111542343A (en) * | 2018-08-24 | 2020-08-14 | 深圳普瑞金生物药业有限公司 | Single domain antibody against BCMA and uses thereof |
| CN112552415A (en) * | 2021-02-22 | 2021-03-26 | 北京百普赛斯生物科技股份有限公司 | B lymphocyte stimulating factor dodecamer, and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1492878A (en) * | 2000-06-16 | 2004-04-28 | �Ϻ���ͨ��ѧ | Antibody that immunospecifically bind to BLYS |
| CN103421113A (en) * | 2012-05-22 | 2013-12-04 | 武汉华鑫康源生物医药有限公司 | Anti-BLyS antibody |
| CN103497253A (en) * | 2013-09-26 | 2014-01-08 | 东南大学 | Nanometer antibody, encoding sequence and application of H2A.Z variant |
-
2014
- 2014-01-29 CN CN201410046314.5A patent/CN104804092B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1492878A (en) * | 2000-06-16 | 2004-04-28 | �Ϻ���ͨ��ѧ | Antibody that immunospecifically bind to BLYS |
| CN103421113A (en) * | 2012-05-22 | 2013-12-04 | 武汉华鑫康源生物医药有限公司 | Anti-BLyS antibody |
| CN103497253A (en) * | 2013-09-26 | 2014-01-08 | 东南大学 | Nanometer antibody, encoding sequence and application of H2A.Z variant |
Non-Patent Citations (1)
| Title |
|---|
| 刘微等: "骆驼纳米抗体在医疗领域研究进展", 《动物医学进展》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108251442A (en) * | 2018-02-07 | 2018-07-06 | 中国医学科学院血液病医院（血液学研究所） | FLT3 Chimeric antigen receptors and its application |
| CN111542343A (en) * | 2018-08-24 | 2020-08-14 | 深圳普瑞金生物药业有限公司 | Single domain antibody against BCMA and uses thereof |
| CN111542343B (en) * | 2018-08-24 | 2023-08-18 | 上海先博生物科技有限公司 | anti-BCMA single domain antibodies and uses thereof |
| CN110776564A (en) * | 2019-10-30 | 2020-02-11 | 西北农林科技大学 | Two-strain anti-newcastle disease virus nano antibody and expression preparation method and application thereof |
| CN110776564B (en) * | 2019-10-30 | 2022-02-08 | 西北农林科技大学 | Two-strain anti-newcastle disease virus nano antibody and expression preparation method and application thereof |
| CN112552415A (en) * | 2021-02-22 | 2021-03-26 | 北京百普赛斯生物科技股份有限公司 | B lymphocyte stimulating factor dodecamer, and preparation method and application thereof |
| CN112552415B (en) * | 2021-02-22 | 2021-06-22 | 北京百普赛斯生物科技股份有限公司 | B lymphocyte stimulating factor dodecamer, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104804092B (en) | 2018-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017305366B2 (en) | Anti-PD-L1 nanobody and use thereof | |
| JP7289562B2 (en) | Anti-BCMA single domain antibody and its application | |
| CN105087788A (en) | Immunomagnetic bead for sorting human cells and preparation and cutting-off method of immunomagnetic bead | |
| CN109503716A (en) | A kind of bispecific chimeric antigen receptor molecule and its application in oncotherapy | |
| CN104804092A (en) | Nanometer antibody for resisting B cell growth stimulating factor and use thereof | |
| CN104804090B (en) | Nano antibody for resisting B cell growth stimulating factor and application | |
| CN117126280B (en) | Anti-human BCMA nanobody with hydrophilic amino acid residues, CAR-T and application | |
| CN104031148A (en) | Monoclonal antibody aiming at human PrPc and application thereof | |
| CN109912718A (en) | Isolated binding protein, nucleic acid, carrier, CAR-T cell and its application of B7-H3 antigen-binding domains | |
| CN113214406B (en) | Preparation method and application of fusion protein combined with GPC3 | |
| CN116143943B (en) | Targeting BAFFR chimeric antigen receptor, CAR-T cell and application | |
| CN114685664B (en) | Single-domain antibody for resisting human B lymphocyte surface antigen CD20 and application thereof | |
| CN114163538B (en) | Chimeric antigen receptor and chimeric antigen receptor T cell simultaneously targeting GPC3 and CD276, and preparation methods and applications thereof | |
| CN102719399A (en) | In vitro amplification method of self-specific T cell, prepared T cell system, pharmaceutical use of cell system and component monitoring method of cell system | |
| CN104804091B (en) | Nano antibody for resisting B cell growth stimulating factor and application | |
| CN116410312A (en) | Development of novel UPAR single domain antibody | |
| CN111333732A (en) | Preparation and application of bispecific antibody targeting human BCMA and activating NK cells | |
| CN115124618B (en) | Application of immune cells separated from autoblood in treating diseases | |
| CN111484558A (en) | Signal regulatory protein α fragment-anti-FcRn single-chain antibody fusion protein, and preparation and application thereof | |
| CN115124619B (en) | Preparation method and application of clinical blood immune cells | |
| CN103382218A (en) | Cell-penetrating peptide and pharmaceutical composition and preparation method and application thereof | |
| CN114805581B (en) | Antibodies targeting IL13RA2, chimeric antigen receptors and uses thereof | |
| CN116970081B (en) | Anti-humanized CD132 monoclonal antibody and application thereof | |
| CN105669837A (en) | Vascular endothelial cadherin epitope, antibody and application thereof | |
| CN116655794A (en) | Immune cell of targeted T cell lymphoma cell and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180327 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |